China Biologic Products Holdings, Inc.
China Biologic Products Holdings, Inc., is a leading fully integrated plasma-based biopharmaceutical company in China. China Biologic's core capabilities include plasma collection, and the manufacturing and commercialization of human plasma-based biopharmaceutical products. These products are used as critical therapies during medical emergencies, and for the prevention and treatment of life-threatening diseases, and immune-deficiency related diseases. Backed by robust research and development capabilities, China Biologic aims to capture substantial value along the entire plasma products value chain, develop technology to enhance production efficiency, and meet the growing demand of patients. China Biologic manufactures its products through a wholly-owned facility in Guizhou Province, majority-owned facility in Shandong Province, and minority-owned facility in Shaanxi Province. China Biologic's well-managed and strategically located plasma collection stations under these facilities secure the raw material to manufacture these products.
As China Biologic focuses on its core plasma business, it has expanded its product pipeline to include non-plasma biopharmaceutical products and bio-medical device products to complement its market position, and expand its base of users in the growing core plasma therapeutic business. With a goal of building a world class biopharmaceutical and biotechnology company, China Biologic is committed to improving quality of life and creating value for more patients.
Location of Key Operations
KPMG Huazhen LLP
IPO (April 3, 2007)
Guizhou, Shandong, & Shaanxi
April 20, 2021: China Biologic Announces Completion of Going Private Transaction
January 25, 2021: China Biologic Announces Extraordinary General Meeting of Shareholders